Enlife Bags Rs 6 Crore for Indian Alzheimer’s Blood Test

Innovative Early Detection of Neurodegenerative Diseases

The Bengaluru-based deeptech startup eNLife Research has secured Rs 6 crore in seed funding to advance its AI-powered Alzheimer’s blood test. Specifically, this funding will help the company build and validate its blood-based biomarker platform. Piper Serica VC Fund led the seed round. Consequently, the company can now expand its research team and transition its prototype to a clinical-grade assay. Dr. Deepak Kumaran Nair, Lt. Col. Jojo Jacob, and Anish Mathew founded the company. Currently, they are driving healthcare innovation in India.

The Clinical Need for an Alzheimer’s Blood Test

Today, clinicians rely on PET scans, MRIs, and cerebrospinal fluid analysis for diagnosis. However, these traditional methods are highly expensive and invasive. Moreover, they generally identify the disease only a year or two before symptoms appear. Therefore, patients often miss the critical window for early intervention. In contrast, Enlife is developing a simple blood test that could detect Alzheimer’s up to 15 years in advance. This test would significantly improve patient outcomes by enabling earlier clinical care, a vital aspect for those looking to expand their expertise through advanced training in dementia care.

Leveraging Artificial Intelligence and Biomarker Tracking

Currently, the company’s platform screens for five to seven biomarkers, including amyloid beta and abnormal tau proteins. Meanwhile, the startup plans to expand this panel to track up to 100 biological markers. This expansion will enable the AI platform to recognize complex disease patterns. Furthermore, the company simulates laboratory work using machine learning. As a result, this technology significantly reduces diagnostic development times and overall costs. The startup aims to partner with hospital chains and diagnostic laboratories across the country.

Tailoring Diagnostics for the Indian Population

Most existing diagnostic models rely entirely on Western patient cohorts. Consequently, they do not work well for the genetically diverse Indian population. To address this gap, Enlife is collaborating with premier research institutions like IISc, NIMHANS, TIFR, and CBR. Together, they are building India-specific biomarker datasets. In addition, the company expects to begin filing patents over the next nine to 18 months. Ultimately, this technology designed for Bharat will make screening accessible even in tier 2 and tier 3 cities, supporting advancements in modern neurology diagnostics.

Frequently Asked Questions

Q1: How early can the Enlife blood test detect Alzheimer’s disease?

The AI-powered diagnostic platform aims to detect biological signs of Alzheimer’s disease up to 15 years before clinical symptoms emerge.

Q2: Who are the key collaborators in this diagnostic initiative?

Enlife is collaborating with leading Indian research institutes, including IISc, NIMHANS, CBR Bengaluru, and TIFR Hyderabad, to develop population-specific biomarker datasets.

References

1. Deeptech startup Enlife bags Rs 6 crore to develop AI blood test for Alzheimer’s – ETHealthworld
2. eNLife Research raises ₹6 Cr seed funding led by Piper Serica VC Fund – Entrepreneur
3. eNLife Research raises ₹6 crore in seed funding – Medical Buyer

Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.